UY31976A - Derivados de triazol útiles para el tratamiento de enfermedades - Google Patents
Derivados de triazol útiles para el tratamiento de enfermedadesInfo
- Publication number
- UY31976A UY31976A UY0001031976A UY31976A UY31976A UY 31976 A UY31976 A UY 31976A UY 0001031976 A UY0001031976 A UY 0001031976A UY 31976 A UY31976 A UY 31976A UY 31976 A UY31976 A UY 31976A
- Authority
- UY
- Uruguay
- Prior art keywords
- diseases
- useful
- treatment
- triazol derivatives
- derivatives
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de fórmula (1) y a procedimientos para la preparación de, intermedios usados en la preparación de, composiciones que los contienen y al uso de, tales derivados. Los compuestos de acuerdo con la presente invención son útiles en numerosas enfermedades, trastornos y afecciones, en particular enfermedades, trastornos y afecciones inflamatorias, alérgicas y respiratorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7983708P | 2008-07-11 | 2008-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31976A true UY31976A (es) | 2010-02-26 |
Family
ID=41078162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001031976A UY31976A (es) | 2008-07-11 | 2009-07-09 | Derivados de triazol útiles para el tratamiento de enfermedades |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8263623B2 (es) |
| EP (1) | EP2300443B1 (es) |
| JP (1) | JP5608162B2 (es) |
| KR (1) | KR101235962B1 (es) |
| CN (1) | CN102089290B (es) |
| AP (1) | AP2010005508A0 (es) |
| AR (1) | AR072488A1 (es) |
| AU (1) | AU2009269610B2 (es) |
| BR (1) | BRPI0915897A2 (es) |
| CA (1) | CA2726686C (es) |
| CO (1) | CO6321248A2 (es) |
| CR (1) | CR11818A (es) |
| DK (1) | DK2300443T3 (es) |
| DO (1) | DOP2011000010A (es) |
| EA (1) | EA201001821A1 (es) |
| EC (1) | ECSP11010754A (es) |
| ES (1) | ES2398428T3 (es) |
| IL (1) | IL209730A (es) |
| MA (1) | MA32466B1 (es) |
| MX (1) | MX2011000352A (es) |
| NI (1) | NI201100006A (es) |
| NZ (1) | NZ589613A (es) |
| PE (1) | PE20110151A1 (es) |
| SV (1) | SV2011003802A (es) |
| TW (1) | TW201006822A (es) |
| UA (1) | UA99524C2 (es) |
| UY (1) | UY31976A (es) |
| WO (1) | WO2010004517A1 (es) |
| ZA (1) | ZA201100534B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011143106A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bi - functional pyrazolopyridine compounds |
| JP5807058B2 (ja) * | 2010-05-10 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | 二機能キノリン誘導体 |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| KR101840852B1 (ko) | 2011-10-10 | 2018-03-22 | 삼성전자주식회사 | 모바일 장치의 표면 온도 관리 방법 및 멀티칩 패키지의 메모리 열관리 방법 |
| KR101857529B1 (ko) | 2011-11-08 | 2018-05-15 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그것의 구동 방법 |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| DE102012111829B4 (de) | 2011-12-06 | 2024-10-10 | Samsung Electronics Co., Ltd. | Speichersysteme und Blockkopierverfahren davon |
| KR101859646B1 (ko) | 2011-12-16 | 2018-05-18 | 삼성전자주식회사 | 보안 데이터를 보호하는 메모리 장치 및 보안 데이터를 이용한 데이터 보호 방법 |
| DE102013100596B4 (de) | 2012-01-27 | 2023-09-07 | Samsung Electronics Co. Ltd. | Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren |
| KR101903440B1 (ko) | 2012-02-21 | 2018-10-02 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그것의 접지 선택 트랜지스터의 문턱전압 조절 방법 |
| DE102013105356A1 (de) | 2012-05-29 | 2013-12-05 | Samsung Electronics Co., Ltd. | Verfahren zum Betreiben von nichtflüchtigen Speichervorrichtungen, die effiziente Fehlererkennung unterstützen |
| KR101996004B1 (ko) | 2012-05-29 | 2019-07-03 | 삼성전자주식회사 | 비휘발성 메모리 장치의 프로그램 방법 및 그것의 메모리 시스템 |
| KR102000634B1 (ko) | 2012-06-07 | 2019-07-16 | 삼성전자주식회사 | 비휘발성 메모리 장치 및 그것의 소거 방법 |
| KR102025263B1 (ko) | 2012-10-05 | 2019-09-25 | 삼성전자주식회사 | 메모리 시스템 및 그것의 읽기 교정 방법 |
| KR102025251B1 (ko) | 2012-10-31 | 2019-09-25 | 삼성전자주식회사 | 메모리 시스템 및 그것의 프로그램 방법 |
| EP2934594B1 (en) | 2012-12-18 | 2019-09-04 | Almirall, S.A. | Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities . |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| KR102068342B1 (ko) | 2013-03-07 | 2020-01-20 | 삼성전자주식회사 | 메모리 제어기 및 그것을 포함하는 메모리 시스템 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| KR102187643B1 (ko) | 2013-12-04 | 2020-12-08 | 삼성전자주식회사 | 메모리 시스템 및 그것을 포함하는 유저 장치 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| US11447485B2 (en) | 2016-12-14 | 2022-09-20 | Beijing Showby Pharmaceutical Co., Ltd. | Class of bifunctional compounds with quanternary ammonium salt structure |
| CN107194205B (zh) * | 2017-05-31 | 2020-11-24 | 浙江大学 | 具有杀菌活性的jak2激酶抑制剂及其虚拟筛选方法 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750540A (en) | 1995-04-28 | 1998-05-12 | Banyu Pharmaceutical Co., Ltd. | 1,4-di-substituted piperidine derivatives |
| GB9603755D0 (en) | 1996-02-22 | 1996-04-24 | Pfizer Ltd | Therapeutic agents |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| PT1353919E (pt) | 2000-12-28 | 2006-11-30 | Almirall Prodesfarma Ag | Novos derivados de quinuclidina e composições medicinais contendo os mesmos |
| DE10200943A1 (de) | 2002-01-12 | 2003-07-24 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Scopinestern |
| US7232835B2 (en) | 2002-12-10 | 2007-06-19 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CN101239970B (zh) * | 2003-02-14 | 2011-07-20 | 施万制药 | 联苯衍生物 |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| US7317102B2 (en) | 2003-04-01 | 2008-01-08 | Theravance, Inc. | Diarylmethyl and related compounds |
| WO2004106333A1 (en) | 2003-05-28 | 2004-12-09 | Theravance, Inc. | Azabicycloalkane compounds as muscarinic receptor antagonists |
| ES2289691T3 (es) * | 2004-01-22 | 2008-02-01 | Pfizer, Inc. | Derivados de sulfonamida para el tratamiento de enfermedades. |
| US7538141B2 (en) * | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| WO2005092840A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Formamide derivatives useful as adrenoceptor |
| EP1833822A2 (en) * | 2004-08-16 | 2007-09-19 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| TW200745084A (en) * | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2008023157A1 (en) | 2006-08-21 | 2008-02-28 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as m3-receptor modulators |
-
2009
- 2009-07-01 US US12/496,054 patent/US8263623B2/en not_active Expired - Fee Related
- 2009-07-08 AR ARP090102593A patent/AR072488A1/es not_active Application Discontinuation
- 2009-07-09 KR KR1020117000612A patent/KR101235962B1/ko not_active Expired - Fee Related
- 2009-07-09 ES ES09786555T patent/ES2398428T3/es active Active
- 2009-07-09 UY UY0001031976A patent/UY31976A/es not_active Application Discontinuation
- 2009-07-09 WO PCT/IB2009/052986 patent/WO2010004517A1/en not_active Ceased
- 2009-07-09 NZ NZ589613A patent/NZ589613A/en not_active IP Right Cessation
- 2009-07-09 EA EA201001821A patent/EA201001821A1/ru unknown
- 2009-07-09 DK DK09786555.4T patent/DK2300443T3/da active
- 2009-07-09 CA CA2726686A patent/CA2726686C/en not_active Expired - Fee Related
- 2009-07-09 AU AU2009269610A patent/AU2009269610B2/en not_active Ceased
- 2009-07-09 MX MX2011000352A patent/MX2011000352A/es active IP Right Grant
- 2009-07-09 UA UAA201014259A patent/UA99524C2/ru unknown
- 2009-07-09 EP EP09786555A patent/EP2300443B1/en active Active
- 2009-07-09 AP AP2010005508A patent/AP2010005508A0/xx unknown
- 2009-07-09 CN CN2009801271934A patent/CN102089290B/zh not_active Expired - Fee Related
- 2009-07-09 BR BRPI0915897A patent/BRPI0915897A2/pt not_active IP Right Cessation
- 2009-07-09 JP JP2011517301A patent/JP5608162B2/ja not_active Expired - Fee Related
- 2009-07-09 PE PE2011000007A patent/PE20110151A1/es not_active Application Discontinuation
- 2009-07-10 TW TW098123536A patent/TW201006822A/zh unknown
-
2010
- 2010-11-26 CR CR11818A patent/CR11818A/es not_active Application Discontinuation
- 2010-12-02 IL IL209730A patent/IL209730A/en not_active IP Right Cessation
- 2010-12-22 CO CO10160881A patent/CO6321248A2/es not_active Application Discontinuation
-
2011
- 2011-01-05 NI NI201100006A patent/NI201100006A/es unknown
- 2011-01-07 DO DO2011000010A patent/DOP2011000010A/es unknown
- 2011-01-10 SV SV2011003802A patent/SV2011003802A/es unknown
- 2011-01-10 MA MA33507A patent/MA32466B1/fr unknown
- 2011-01-11 EC EC2011010754A patent/ECSP11010754A/es unknown
- 2011-01-20 ZA ZA2011/00534A patent/ZA201100534B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY31976A (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
| AR059963A1 (es) | Derivados de amina | |
| UY28724A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| CR8649A (es) | Derivados de formamidina para el tratamiento de enfermedades | |
| CR10700A (es) | Derivados de sulfonamida | |
| UY28721A1 (es) | Derivados de sulfonamida para eltratamiento de enfermedades | |
| ECSP056164A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
| CR8636A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| ECSP099328A (es) | Análogos de pirazol | |
| CU20110002A7 (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
| DOP2005000037A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| CU23532B7 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| CU23537B7 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| CU23661B7 (es) | Derivados de formamida para el tratamiento de enfermedades | |
| DOP2005000045A (es) | Derivados de formamida para el tratamiento de enfermedades | |
| UY28810A1 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| UY28816A1 (es) | Compuestos para el tratamiento de enfermedades | |
| DOP2004000902A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| GT200500056A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| DOP2007000054A (es) | Derivados de amina | |
| DOP2005000041A (es) | Compuestos para el tratamientos de enfermandades | |
| ECSP066700A (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| DOP2005000043A (es) | Compuestos para el tratamiento de enfermedades | |
| DOP2004000921A (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20181107 |